Bio-path Holdings Stock News

Turn Therapeutics (NASDAQ: TTRX - Get Free Report) and Bio-Path (NASDAQ: BPTH - Get Free Report) are both small-cap manufacturing companies, but which is the superior investment? We will compare the t

  Pittsburgh, PA — February 4, 2026 -- InvestorsHub NewsWire -- Bio-Path Holdings, Inc. (OTC Pink:BPTH) ("Bio-Path" or the "Company"), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery technology, today announced its "BPTH 2.0" strategic roadmap. As part of this transition, the Company has engaged securities counsel to prepare a Regulation A Offering Statement for filing with the SEC.   "The B...

Institutional and Insider Ownership 5.7% of Bio-Path shares are held by institutional investors. 34.4% of Amarillo Biosciences shares are held by insiders. Comparatively, 0.7% of Bio-Path shares are h

Dallas, Texas--(Newsfile Corp. - June 4, 2025) - Bio-Path Holdings, Inc. (OTCQB: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (OTCQB: BPTH) for Q1 2025. Bio-Path Holdi

Highlights Promise of DNAbilize® Platform to Produce New Drug Candidates and Potential Licensing Opportunities Highlights Promise of DNAbilize® Platform to Produce New Drug Candidates and Potential

HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portf

Data suggest BP1001-A prevents fatty acid-induced insulin resistance in cells Data suggest BP1001-A prevents fatty acid-induced insulin resistance in cells

HOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a po

Recent Pre-Clinical Studies Showed BP1001-A Attenuated Fatty Acid-Induced Insulin Resistance and Restored Insulin Sensitivity in Muscle Progenitor and Skeletal Muscle Fiber Cell Models Recent Pre-Clin

First Solid Tumor Patient Treated with Second, Higher Dose in Phase 1/1b BP1001-A Clinical Trial Experienced Tumor Reduction and Continued Stable Disease

Study Progresses to Fourth Higher 90 mg/m 2 Dose Cohort Compelling Patient Response Highlighted by Stable Disease and Significant Reduction in Blast Count After One Treatment Cycle HOUSTON, Feb. 12, 2

Advancing Multiple Programs in Areas of Significant Unmet Medical Need Several Milestones Across Clinical Development Pipeline Expected in 2025 HOUSTON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Bio-Path Hold

Preclinical Studies Confirmed BP1001-A Mechanism of Action and Therapeutic Potential in Obesity and Type 2 Diabetes Preclinical Studies Confirmed BP1001-A Mechanism of Action and Therapeutic Potential

Dallas, Texas--(Newsfile Corp. - December 13, 2024) - Bio-Path Holdings, Inc. (NASDAQ: BPTH): Stonegate Capital Partners Updates Coverage on Bio-Path Holdings, Inc. (NASDAQ: BPTH) for Q3 2024. To view

Extensive Scientific Evidence Supporting Growth Factor Receptor Bound Protein-2 (Grb2) as Fundamental Link in Insulin Resistance